ALLK News and Press, Allakos Inc. From 10/18/22

Summary Results from the phase 2b study, using lirentelimab for the treatment of patients with chronic spontaneous urticaria, are expected in the 2nd half of 2023. Xolair naive CSU cohort of 13 patients started with an average UAS7 score of 18.5 points at baseline and at week 22 d...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Fed’s key interest  rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive. As a result,...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips On Monday, biotechnology firm Allakos (NASDAQ: ALLK ) announced a public offering that raised gross proceeds of approximately $150 million , sending ALLK stock soaring 25% in the morning session before paring back mode...

Biotechnology company Allakos ( NASDAQ: ALLK ) is pricing an underwritten offering of 29.9M shares at $5.02 per share. The expected gross proceeds from the offering, estimated to close on or about Sep. 21, will be ~$150M. Logos Capital, Alta Partners, Br...

SAN CARLOS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the pricing of an underwritten offering of 29,882,000 shares of its ...

SAN CARLOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced it has initiated a Phase 2b clinical trial to evaluate the efficacy,...

The shares of clinical-stage biotech Allakos ( NASDAQ: ALLK ) dropped ~12% in the pre-market Friday after the company announced mixed results from its Phase 3 trial for lead asset lirentelimab in eosinophilic duodenitis ((EoD)), an inflammatory condition in the gastrointes...

– Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint – SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK...

Shares of the beaten-down biotech Allakos (NASDAQ: ALLK) are showing signs of life today. Specifically, the clinical-stage immunomodulatory receptor specialist's stock price was up by a healthy 24.7%, on heavy volume, as of 1:15 p.m. ET Wednesday afternoon. What's powering t...

Gainer: Kinnate Biopharma ( KNTE ) +5% . Kezar Life Sciences ( KZR ) +5% . BridgeBio Pharma ( BBIO ) +5% . Stronghold Digital Mining ( SDIG ) +3% . IDEAYA Biosciences ( IDYA ) +3% . Losers: Advanced Emissions Solutions ( ...